All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. Do innovative medicines against cancer always have a real added value?

    KCE Reports 343 (2021)  

    https://kce.fgov.be/en/do-innovative-medicines-against-cancer-always-have-a-real-added-value
  2. Pils

    Guideline on the prudent prescription of antibiotics in the dental office

    KCE Reports R332C

    https://kce.fgov.be/en/guideline-on-the-prudent-prescription-of-antibiotics-in-the-dental-office
  3. Antibiotic_Policy

    Proposals for a more effective antibiotic policy in Belgium

    KCE Reports 311 (2019)  

    https://kce.fgov.be/en/proposals-for-a-more-effective-antibiotic-policy-in-belgium
  4. Children in a playground

    Cost-effectiveness analysis of HPV vaccination of boys in Belgium

    KCE Reports 308 (2019) The vaccine for the human papilloma virus (HPV) which causes cervical cancer was introduced about ten years ago in Belgium, but only girls benefit from it. However, it is now established that this same virus is also involved in other cancers, including throat cancer. The recommendations have thus been reviewed and here, as in most western countries, it is now recommended to vaccinate boys too.

    https://kce.fgov.be/en/cost-effectiveness-analysis-of-hpv-vaccination-of-boys-in-belgium
  5. Senior couple on contry bike

    Statins for the primary prevention of cardiovascular events

    KCE Reports 306 (2019) A healthy lifestyle remains the most effective way of avoiding cardiovascular diseases and their consequences. Yet since 2002, the annual number of people who use cholesterol-lowering drugs from the statin family increased from 400,000 to 1,500,000. Currently, 25% of the population aged 40 and above take these drugs. Despite decreases in price due to the fact that all statins now exist in generic form, their total cost still stands at 160 million euros annually.

    https://kce.fgov.be/en/statins-for-the-primary-prevention-of-cardiovascular-events

  6. Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C

    KCE Reports 276 (2016)

    https://kce.fgov.be/en/publication/report/economic-evaluation-of-novel-direct-acting-antiviral-daa-treatment-strategies-for

  7. Use of pneumococcal vaccines in the elderly: an economic evaluation

    KCE Reports 274 (2016) Supplementary material pdf fileR274_Supplementary-file_Univariate-sensitivity-analyses (13.95 MB) pdf fileR274_Supplementary-file_Sensitivity-analyses_PPV23-price (1.1 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_Net-benefit-Box-plots (1.16 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_CEAFs-and-CE-planes (58.74 MB) The results are also available in a searchable spreadsheet-database format for all scenario and sensitivity analyses.

    https://kce.fgov.be/en/publication/report/use-of-pneumococcal-vaccines-in-the-elderly-an-economic-evaluation

  8. Future scenarios about drug development and drug pricing

    KCE Reports 271 (2016)

    https://kce.fgov.be/en/publication/report/future-scenarios-about-drug-development-and-drug-pricing

  9. Towards a better managed off-label use of drugs

    KCE Reports 252 (2015)

    https://kce.fgov.be/en/publication/report/towards-a-better-managed-off-label-use-of-drugs

  10. Publicly funded Practice-oriented Clinical Trials

    KCE Reports 246 (2015)

    https://kce.fgov.be/en/publication/report/publicly-funded-practice-oriented-clinical-trials

  11. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

    KCE Reports 231 (2014)

    https://kce.fgov.be/en/publication/report/a-quadrivalent-vaccine-against-serogroup-b-meningococcal-disease-a-cost-effective

  12. The long-term efficacy of psychotherapy, alone or in combination with antidepressants, in the treatment of adult major depression

    Please take note of the publication date of this guideline. From a methodological point of view, a guideline is generally considered obsolete after 5 years. It is therefore possible that some parts of this document are no longer relevant. KCE Reports 230 (2014)

    https://kce.fgov.be/en/publication/report/the-long-term-efficacy-of-psychotherapy-alone-or-in-combination-with-antidepressa

  13. Supportive treatment for cancer – Part 3: Treatment of pain: most common practices

    Please take note of the publication date of this guideline. From a methodological point of view, a guideline is generally considered obsolete after 5 years. It is therefore possible that some parts of this document are no longer relevant. KCE Reports 211 (2013)

    https://kce.fgov.be/en/publication/report/supportive-treatment-for-cancer-%E2%80%93-part-3-treatment-of-pain-most-common-practices

  14. Barriers and opportunities for the uptake of biosimilar medicines in Belgium

    KCE Reports 199 (2013)

    https://kce.fgov.be/en/publication/report/barriers-and-opportunities-for-the-uptake-of-biosimilar-medicines-in-belgium

  15. Supportive treatment for cancer - Part 2: Prevention and treatment of adverse events related to chemotherapy and radiotherapy

    Please take note of the publication date of this guideline. From a methodological point of view, a guideline is generally considered obsolete after 5 years. It is therefore possible that some parts of this document are no longer relevant. KCE Reports 191 (2012)

    https://kce.fgov.be/en/publication/report/supportive-treatment-for-cancer-part-2-prevention-and-treatment-of-adverse-events

  16. [Vaccine safety surveillance in Belgium : place and limits of a background rate approach]

    KCE Reports 188 (2012)

    https://kce.fgov.be/en/publication/report/vaccine-safety-surveillance-in-belgium-place-and-limits-of-a-background-rate-appr

  17. [Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

    KCE Reports 157 (2011)

    https://kce.fgov.be/en/publication/report/economic-evaluation-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium

  18. Pharmacological prevention of fragility fractures in Belgium

    Please take note of the publication date of this guideline. From a methodological point of view, a guideline is generally considered obsolete after 5 years. It is therefore possible that some parts of this document are no longer relevant. KCE Reports 159 (2011)

    https://kce.fgov.be/en/publication/report/pharmacological-prevention-of-fragility-fractures-in-belgium

  19. Drug reimbursement systems: international comparison and policy recommendations

    KCE Reports 147 (2010)

    https://kce.fgov.be/en/publication/report/drug-reimbursement-systems-international-comparison-and-policy-recommendations-0

  20. [Statins in Belgium: utilization trends and impact of reimbursement policies]

    KCE Reports 141 (2010)

    https://kce.fgov.be/en/publication/report/statins-in-belgium-utilization-trends-and-impact-of-reimbursement-policies

Pages